Among patients with MCL still on study in January 2025, 35.3% reported improved MCL-related symptoms, while 5.9% reported ...
When Nathan was diagnosed with chronic lymphocytic leukemia (CLL) at just 45 years old, his world turned upside down overnight. As a military veteran and ER nurse, he was no stranger to facing ...
Zanubrutinib shows safety and efficacy in CLL/SLL patients, regardless of prior ibrutinib treatment, with lower treatment-limiting and cardiac adverse events compared to ibrutinib. The study included ...
Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility ...
BGB-16673, a BTK degrader, targets relapsed/refractory CLL/SLL, showing promising efficacy in heavily pretreated patients. The FDA's fast track designation aims to expedite drug development for ...
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center ...
LBA-3: Pirtobrutinib vs Bendamustine Plus Rituximab (BR) in Patients with CLL/SLL: First Results from a Randomized Phase III Study Examining a Non-Covalent BTK Inhibitor in Untreated Patients ORLANDO, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results